Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic impact of depth of response and early tumour shrinkage in patients with BRAF V600E -mutated metastatic colorectal cancer treated with targeted therapy.
Vetere G, Germani MM, Antoniotti C, Salvatore L, Pietrantonio F, Lonardi S, Bensi M, Ghelardi F, Calegari MA, Intini R, Minelli A, Sullo FG, Boccaccio C, Taravella A, Puccini A, Lavacchi D, Noto L, Salati M, Scartozzi M, Cremolini C. Vetere G, et al. Ther Adv Med Oncol. 2025 Jan 7;17:17588359241299975. doi: 10.1177/17588359241299975. eCollection 2025. Ther Adv Med Oncol. 2025. PMID: 39776534 Free PMC article.
Mutational and co-mutational landscape of early onset colorectal cancer.
Alshenaifi JY, Vetere G, Maddalena G, Yousef M, White MG, Shen JP, Vilar E, Parseghian C, Dasari A, Morris VK, Huey R, Overman MJ, Wolff R, Raghav KP, Willis J, Alfaro K, Futreal A, You YN, Kopetz S. Alshenaifi JY, et al. Among authors: vetere g. Biomarkers. 2025 Jan 9:1-13. doi: 10.1080/1354750X.2024.2447089. Online ahead of print. Biomarkers. 2025. PMID: 39761813
KRASG12D-Mutated Metastatic Colorectal Cancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted Alteration.
Moretto R, Rossini D, Murgioni S, Ciracì P, Nasca V, Germani MM, Calegari MA, Vetere G, Intini R, Taravella A, Studiale V, Boccaccio C, Passardi A, Tamburini E, Zaniboni A, Salvatore L, Pietrantonio F, Lonardi S, Masi G, Cremolini C. Moretto R, et al. Among authors: vetere g. JCO Precis Oncol. 2024 Nov;8:e2400329. doi: 10.1200/PO.24.00329. Epub 2024 Nov 7. JCO Precis Oncol. 2024. PMID: 39509668
Unveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers: a marker of peritoneal carcinomatosis burden.
Provenzano L, Gwee YX, Conca V, Lonardi S, Bozzarelli S, Tamburini E, Passardi A, Zaniboni A, Tosi F, Aprile G, Nasca V, Boccaccino A, Ambrosini M, Vetere G, Carullo M, Guaglio M, Battaglia L, Zhao JJ, Chia DKA, Yong WP, Tan P, So J, Kim G, Shabbir A, Ong CJ, Casella F, Cremolini C, Bencivenga M, Sundar R, Pietrantonio F. Provenzano L, et al. Among authors: vetere g. Ther Adv Med Oncol. 2024 Nov 4;16:17588359241289517. doi: 10.1177/17588359241289517. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39502404 Free PMC article.
Induction treatment with FOLFIRINOX or oxaliplatin-based doublet followed by long-course chemoradiotherapy and surgery in locally advanced rectal cancer. A systematic review and pooled analysis from phase II and III trials.
Moretto R, Vetere G, Carullo M, Ciracì P, Masi G, Cremolini C. Moretto R, et al. Among authors: vetere g. Cancer Treat Rev. 2024 Nov;130:102829. doi: 10.1016/j.ctrv.2024.102829. Epub 2024 Sep 16. Cancer Treat Rev. 2024. PMID: 39305700
Interpretation of long-term overall survival from the PRODIGE 23 study. Letter to the Editor regarding 'Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial', by T. Conroy et al.
Moretto R, Vetere G, Di Maio M. Moretto R, et al. Among authors: vetere g. Ann Oncol. 2024 Nov;35(11):1063-1064. doi: 10.1016/j.annonc.2024.08.2331. Epub 2024 Aug 28. Ann Oncol. 2024. PMID: 39214461 No abstract available.
Treatment of patients with BRAFV600E-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset.
Germani MM, Vetere G, Santamaria F, Intini R, Ghelardi F, Bensi M, Boccaccino A, Minelli A, Carullo M, Ciracì P, Passardi A, Santucci S, Giampieri R, Persano M, Fenocchio E, Puccini A, Lonardi S, Pietrantonio F, Salvatore L, Cremolini C. Germani MM, et al. Among authors: vetere g. ESMO Open. 2024 Apr;9(4):102996. doi: 10.1016/j.esmoop.2024.102996. Epub 2024 Apr 12. ESMO Open. 2024. PMID: 38613911 Free PMC article.
48 results